Condition: Non-Small Cell Lung Cancer · EGFR Sensitive Mutation · Adjuvant Therapy · Sponsor: Betta Pharmaceuticals Co., Ltd.
This multicenter, randomized, controlled, double-blind, double-simulated, Phase III study is designed to evaluate the efficacy and safety of Befotertinib compared with Icotinib as adjuvant treatment in EGFR-sensitive mutation-positive stage IB-IIIB (T3N2M0) non-small cell lung cancer after surgical resection.
This description comes directly from the study's public registry record.
Shun Lu, M.D. · +86 21 2220 0000 · shunlu@sjtu.edu.cn
Always discuss trial participation with your own doctor first.
| Peking University International Hospital | Beijing, China | Recruiting |
| Jiangsu Cancer Hospital | Nanjing, China | Recruiting |
| Shanghai chest hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06041776